Full metadata record
DC FieldValueLanguage
dc.creatorMarín-Oto, M. (Marta)-
dc.creatorVicente, E.E. (Eugenio E.)-
dc.creatorMarin, J.M. (José M.)-
dc.date.accessioned2021-11-17T08:54:20Z-
dc.date.available2021-11-17T08:54:20Z-
dc.date.issued2019-
dc.identifier.citationMarin-Oto, M. (Marta); Vicente, E.E. (Eugenio E.); Marin, J.M. (José M.). "Long term management of obstructive sleep apnea and its comorbidities". Multidisciplinary Respiratory Medicine. 14, 2019, 21es_ES
dc.identifier.issn2049-6958-
dc.identifier.urihttps://hdl.handle.net/10171/62590-
dc.description.abstractObstructive sleep apnea (OSA) is a worldwide highly prevalent disease associated with systemic consequences, including excessive sleepiness, impairment of neurocognitive function and daytime performance, including driving ability. The long-term sequelae of OSA include and increase risk for cardiovascular, cerebrovascular and metabolic syndrome disorders that ultimately lead to premature death if untreated. To ensure optimal long-term outcomes, the assessment and management of OSA should be personalized with the involvement of the appropriate specialist. Most studies have demonstrated inmediate improvement in daytime somnolence and quality of life with CPAP and other therapies, but the effect of long-term treatment on mortality is still under debate. Currently, the long-term management of OSA should be based on a) identifying physiological or structural abnormalities that are treatable at the time of patient evaluation and b) comprehensive lifestyle interventions, especially weight-loss interventions, which are associated with improvements in OSA severity, cardiometabolic comorbidities, and quality of life. In long-term management, attention should be paid to the clinical changes related to a potential reoccurrence of OSA symptoms and it is also necessary to monitor throughout the follow up how the main associated comorbidities evolve.es_ES
dc.description.sponsorshipThis work has been funded by Instituto Salud Carlos III (PI18/01524), Ministerio de Ciencia, Innovación y Universidades, Madrid, Spain. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.es_ES
dc.language.isoenges_ES
dc.publisherPAGEPress Publicationses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectObstructive sleep apneaes_ES
dc.subjectCardiovascular diseasees_ES
dc.subjectHypertensiones_ES
dc.subjectDiabeteses_ES
dc.subjectDislipemiaes_ES
dc.subjectLong-term managementes_ES
dc.subjectOutcomeses_ES
dc.titleLong term management of obstructive sleep apnea and its comorbiditieses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.es_ES
dc.identifier.doi10.1186/s40248-019-0186-3-
dadun.citation.publicationNameMultidisciplinary Respiratory Medicinees_ES
dadun.citation.startingPage21es_ES
dadun.citation.volume14es_ES

Files in This Item:
Thumbnail
File
s40248-019-0186-3.pdf
Description
Size
919.87 kB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.